

OIPF
AUG 04 2003
PATENT & TRADEMARK OFFICE

1615
RECEIVED
AUG 07 2003
TECH CENTER
1600/2900
1615

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

**SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT**

Docket Number:
1662/53003

Application Number
10/026,573

Filing Date
December 20, 2001

Examiner
Rachel M. BENNETT

Art Unit
1615

Invention Title
COMPOSITIONS AND DOSAGE FORMS FOR GASTRIC
DELIVERY OF ANTINEOPLASTIC AGENTS AND
METHODS OF TREATMENT THAT USE THEM TO
INHIBIT CANCER CELL PROLIFERATION

Inventor(s)
Moshe FLESHNER-BARAK et al.

Address to:
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

1. In accordance with the duty of disclosure under 37 C.F.R. § 1.56 and in conformance with the procedures of 37 C.F.R. §§ 1.97 and 1.98 and M.P.E.P. § 609, attorneys for Applicants hereby bring the attached reference to the attention of the Examiner. This reference is listed on the attached modified PTO Form No. 1449. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b).
2. A copy of each patent, publication or other information listed on the modified PTO Form No. 1449 is enclosed.
3. The Commissioner is hereby authorized to charge payment of the 37 C.F.R. §1.17(p) (submission of an information disclosure statement under §1.97(c)) fee of **\$180.00** and any additional fees that may be required to the deposit account of **Kenyon & Kenyon**, deposit account number **11-0600**. A copy of this communication is enclosed for charging purposes

Dated: August 4, 2003

By: _____

Paul Johnson
Paul Johnson (Reg. No. 35,559)

08/05/2003 BSAYAS11 00000070 110600 10026573
01 FC:1806 180.00 DA

KENYON & KENYON
1500 K Street, N.W., Suite 700
Washington, DC 20005-1257
(202) 220-4200 (telephone)
(202) 220-4201 (facsimile)



INFORMATION DISCLOSURE STATEMENT BY APPLICANT	DOCKET NO. 1662/53003	SERIAL NO 10/026,573
	APPLICANT FLESHNER-BARAK et al.	
	FILING DATE December 20, 2001	GROUP 1615

U. S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	PATENT DATE	NAME	CLASS	SUBCLASS	FILING DATE*

* - If pertinent

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO

OTHER DOCUMENTS

EXAMINER INITIAL		AUTHOR, TITLE, DATE, PERTINENT PAGES, ETC.
		Takehiko Kunimoto et al., "Antitumor Activity of 7-Ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxy-camptothecin, a Novel Water-soluble Derivative of Camptothecin, Against Murine Tumors," Cancer Research, Vol. 47, No. 22, November 15, 1987, pp. 5944-5947

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with M.P.E.P. 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

RECEIVED
AUG 07 2003
TECH CENTER 1600/2300